Aquaculture is emerging as the fastest growing food-producing industry in the world because of the increasing demand for food fish consumption. However, the intensive culture of food fish has led to outbreaks of various bacterial diseases, resulting in annual economic losses to the aquaculture industry estimated at billions of dollars worldwide. Feeding infected fish with antibiotic-medicated food is a general practice but has led to antibiotic resistance development in bacterial pathogen, resulting in a higher dose requirement for effective control, a matter of increasing public concern. Therefore, alternatives to antibiotics that give similar or enhanced protection to aquatic animals are urgently needed. Various vaccines have been developed recently to combat bacterial diseases in aquaculture. The purpose of this review is to summarize the major bacterial pathogens in aquaculture and the development of vaccines as alternatives to antibiotics to protect aquatic animals from these bacterial diseases.
. Given that bacteria can survive well in aquatic environment independently of their hosts, bacterial diseases have become major impediments to aquaculture, especially when water temperature is warm [18] . Thus far, bacterial species belonging to at least 13 genera have been reported to be pathogenic to aquatic animals, including: (1) Gram-negative bacteria such as Aeromonas, Edwardsiella, Flavobacterium, Francisella, Photobacterium, Piscirickettsia, Pseudomonas, Tenacibaculum, Vibrio and Yersinia; and (2) Gram-positive bacteria such as Lactococcus, Renibacterium and Streptococcus [18] . Major pathogenic Gramnegative and Gram-positive bacterial species reported in disease outbreaks are summarized in Tables 1 and 2 , respectively.
Fresh-water cultured fish as well as marine fish are devastated by bacterial diseases, including tilapia, catfish, carp, trout, salmon, bass, perch, sturgeon and eel. The annual economic loss associated with three bacterial fish pathogens (Aeromonas hydrophila, Yersinia ruckeri and Vibrio fluvialis) between 1990 and 1992 in China was estimated at more than $120 million [168] . Since the value of aquaculture production was estimated at $105.3 billion in 2009 [2] , the global economic impact of bacterial diseases on aquaculture production would be within the range of hundreds of millions to billions of dollars annually.
Control of Bacterial Diseases in Aquaculture
To control bacterial diseases, feeding infected fish with antibiotic-medicated food is a general practice. However, this is usually expensive and may be ineffective because sick fish may remain off feed. In addition, frequent use of antimicrobial compounds has led to the development of resistance to antimicrobial compounds in pathogens, posing serious challenges to health and national security [169] . Resistance can arise in disease-causing bacteria, rendering life-saving antimicrobial compounds ineffective. Furthermore, diseases caused by antibiotic-resistant bacteria are difficult to treat, and there are only a few new antimicrobial compounds in the drug development pipeline. Therefore, alternatives to antimicrobial compounds that give similar or enhanced protection to aquatic animals are urgently needed. An integrated approach that considers not only the pathogen but also the host and the environment will be the most effective method in the long-term to improve aquatic animal health. From the pathogen perspective, besides using antimicrobial compounds, alternative methods in integrated management include: (1) using pathogen-specific bacteriophages; (2) using short-chain fatty acids and polyhydroxyalkanoates to inhibit the growth of bacteria; and (3) using compounds to inhibit virulence gene expression or interrupt the signal transduction pathways of the pathogens [170, 171] . From the environmental perspective of integrated management, good hygiene such as quarantine and disinfection to optimize water quality is important [171] . From the host perspective, it is important to: (1) provide quality feed; (2) prevent stress; (3) improve the breeding stock's disease resistance ability; and (4) adopt the use of immunostimulants or vaccines to improve host immunity [171] . The use of vaccine has been proven to be highly effective in controlling diseases in the salmon industry in Europe, America and Japan [172] . Vaccines have been used in fish, in particular the salmon industry, for approximately 30 years. Vaccination of salmon has dropped the industrial use of antibiotics to a mere fraction of its original use. For example, in 1987, approximately 50,000 kg of antibiotics was used in Norway to control fish diseases (mostly Vibrio spp.) in salmon prior to the widespread use of vaccines [173] . However, by 1997, when an efficacious oil-adjuvant vaccine was extensively used, antibiotic usage had dropped to less than 1000-2000 kg, concurrent with a threefold increase in fish production ( Figure 1 ) [173] . In the following paragraphs, the recent development of vaccines to combat the major bacterial diseases in aquaculture will be reviewed.
Types of Bacterial Vaccines
In general, there are six types of bacterial vaccines: (1) bacterins (killed bacteria) such as the Aeromonas salmonicida bacterin vaccine that is currently available in the USA; (2) attenuated live bacterial vaccine such as the attenuated live Edwardsiella ictaluri vaccine that is commercially available in the USA; (3) toxoid vaccine containing inactivated bacterial toxins rather than the whole bacteria; (4) subunit vaccine such as a protein subunit of the bacterium, where instead of an inactivated or attenuated whole bacterium to stimulate the immune system, a fragment or a subunit of the bacterium is used to stimulate the immune response; (5) conjugate vaccine by conjugating certain membrane proteins of bacteria to other proteins to make the bacterial proteins recognizable, thereby inducing immune response; and (6) experimental vaccines such as DNA vaccines or recombinant vector vaccine. Of the six types of bacterial vaccines, the first two types are commonly used in aquaculture. Modified live vaccines containing live bacteria usually survives and replicates within the host, therefore stimulating a stronger cellular immune response and conferring a longer protection compared with killed vaccines.
Vaccine Development Status for Major Bacterial Diseases in Aquaculture
Currently, eight bacterial fish vaccines are licensed for use in the USA (http://www.aphis.usda.gov/animal_health/ vet_biologics):
(1) A. salmonicida vaccine (bacterin); (2) Arthrobacter vaccine (live culture); 
Aeromonas hydrophila
Motile aeromonads septicaemia Catfish [19] , carp [20, 21] , trout [22, 23] , eel [24] , sturgeon [25] , tilapia [26] and bass [27] Aeromonas salmonicida Furunculosis Salmon [28, 29] , trout [30] , flounder [31] , turbot [32] , carp [33] , tilapia [33] and sole [31] Chryseobacterium sp.
Chryseobacteriosis Salmon [34, 35] and trout [35] 
Edwardsiella ictaluri
Enteric septicaemia of catfish Catfish [36] [37] [38] [39] 
Edwardsiella tarda
Edwardsiellosis or putrefactive disease Turbot [40, 41] , flounder [42, 43] , carp [44] , catfish [45] , eel [45, 46] and tilapia [47, 48] 
Flavobacterium columnare
Columnaris Carp [49, 50] , trout [51, 52] , perch [53] , tilapia [54, 55] , catfish [56] [75] , trout [75] and tilapia [76, 77] Pseudomonas spp. Pseudomonads septicaemia or red spot disease
Seabream [78] , trout [79] , eel [80] , rabbitfish [81] , catfish [82] , eel [83] , shrimp [84] and salmon [85] Tenacibaculum maritimum Tenacibaculosis Sole [86] and turbot [87] Vibrio spp. Vibrosis Croaker fish [88] , puffer fish [89] , grouper [90] , cod [91] , shrimp [92, 93] , big-scale sand smelt [94] , flounder [95] , abalone [96] , seabream [97, 98] , turbot [99, 100] , sole [101] , red drum [102] , cobia [103] , eel [104, 105] , salmon [106] , sweetfish [107] , sheatfish [108] and catfish [109] 
Yersinia ruckeri
Yersiniosis or enteric redmouth disease Trout [110] [111] [112] , tilapia [113] and salmon [114, 115] (3) A. salmonicida-Vibrio anguillarum-Vibrio ordalii-Vibrio salmonicida (Aliivibrio salmonicida) vaccine (bacterin); (4) Flavobacterium columnare vaccine (bacterin); (5) Y. ruckeri vaccine (bacterin); (6) V. anguillarum-V. ordalii vaccine (bacterin); (7) E. ictaluri vaccine (avirulent live culture); (8) F. columnare vaccine (avirulent live culture).
The eight vaccines are licensed for use in aquaculture practices for protection against bacterial diseases. However, vaccines are usually licensed for specific fish species. Therefore, license of certain vaccine for one fish species may not be used to protect another fish species, although the pathogen might be the same. For example, the F. columnare bacterium vaccine is currently licensed for use only in catfish.
Worldwide, vaccines have been developed and commercially available to treat at least 18 bacterial infections [173, 175, 176] : (1) Lactococcosis Yellowtail [116, 117] , trout [118] [119] [120] , rockfish [121] and mullet [122] Nocardia sp.
Nocardiosis Tigerfish [123] , snakehead [124, 125] , croaker [126, 127] , mullet [128] , seabass [129] , largemouth bass [130, 131] , gourami [132] and yellowtail [133] Renibacterium salmoninarum
Bacterial kidney disease
Trout [134] and salmon [135, 136] Staphylococcus spp.
Staphylococcosis
Trout [137] , tilapia [138] , carp [139] , perch [140] , seabream [141, 142] and yellowtail [142] Streptococcus agalactiae Streptococcosis Tilapia [143, 144] Grouper [145] , mullet [146] and pomfret [147] Streptococcus ictaluri
Streptococcosis
Catfish [148] Streptococcus iniae Streptococcosis Tilapia [149] , seabream [150] , red porgy [151] , trout [151] , flounder [152] , barramundi [153] , rabbitfish [154] , hybrid striped bass [155] , yellowtail [156] and catfish [157] Streptococcus dysgalactiae Streptococcosis Sturgeon [158] , amberjack [159, 160] bacteria of pathogenic A. hydrophila strains [184] [185] [186] . In addition, recombinant protein vaccines such as A. hydrophila outer membrane proteins and bacterial lysate have been demonstrated to elicit protection against A. hydrophila challenges in laboratory studies [187] [188] [189] [190] . Furthermore, live attenuated vaccines such as aroA mutant and transposon Tn916-generated mutant have been reported to confer significant protection against homologous A. hydrophila challenge [191, 192] . However, it is well known that A. hydrophila is very heterogeneous biochemically and serologically, thus presenting the biggest obstacle in developing effective commercial vaccine against A. hydrophila [188, 193] . To prevent future disease outbreaks caused by A. hydrophila, a vaccine that could offer protection against multiple serotypes from various regions is urgently needed. (2) Chryseobacteriosis or salmon skin syndrome caused by Chryseobacterium sp. Although members of Chryseobacterium are not relevant pathogens for domestic animal species, they have been associated with diseases of freshwater and marine fish [34, 35, 194] . In addition, Chryseobacterium sp. is reported to be the causative agent of salmon skin syndrome [195] . Therefore, vaccines are needed to protect fish from virulent isolates of Chryseobacterium. in Japan [196] , hybrid striped bass (Morone chrysopsÂ Morone saxatilis) in USA [197] , cod (Gadus morhua) in Norway [198] [199] [200] , tilapia (Oreochromis spp.) in Latin America, Costa Rica, UK and USA [61, [201] [202] [203] , salmon (Salmo salar) in Chile [204] and giant abalone (Haliotis gigantean) in Japan [205] . More aquatic animals are possibly affected by Francisella bacteria because of their fastidious growth condition requiring specialized solid and liquid media containing cysteine and a source of iron, resulting in difficult culture and isolation. Francisellosis in fish develops in a similar fashion independent of host species. The common disease characteristic is the development of multiorgan granuloma and high morbidity [206] . Francisella can be transferred through live fish movement [207] , making Francisellosis a significant threat to aquaculture operations. Experimentally, one deletion mutant of Francisella asiatica iglC has been evaluated as a live attenuated vaccine, which is able to offer significant protection against virulent F. asiatica infections in tilapia [208] . However, no vaccine is currently commercially available to protect fish against infections by Francisella bacteria. (4) Pseudomonad septicaemia or red spot disease caused by Pseudomonas spp. Pseudomonas spp. are emerging fish pathogens responsible for high mortality and disease outbreaks in various fish species.
Pseuodomonas anguilliseptica was first reported in Japanese eels (Anguilla japonica) affected by haemorrhagic septicaemia in Japan [209] . Subsequently, Pseudomonas spp. was recognized as the causative agents of red spot diseases in different aquatic animals, including European eel (Anguilla anguilla) in UK and the Netherlands [81, 85] , Atlantic salmon (S. salar) [210] , sea trout (Salmo trutta) [210] , rainbow trout (Salmo gairdneri), whitefish (Coregonus sp.) in Finland [210] , sea bream (Sparus aurata) in Spain [211, 212] and rainbow trout (Oncorhynchus mykiss) in Turkey [80] . In addition, when combined with parasite, Pseudomonas is responsible for over 70% mortality of sea bream in Egypt [79] . Pseudomonad septicaemia is characterized by high mortality related to a decrease in the water temperatures below 11-12 C [210] . The typical clinical sign is ulceration on the dorsal surface. To prevent diseases caused by Pseudomonas spp., different experimental vaccines have been used. Formalinkilled and heat-inactivated cells of P. anguilliseptica have been reported to offer protection in eels against virulent Pseudomonas infection [213, 214] . Bacterin against P. anguilliseptica was also able to provide protection to turbot (Scophthalmus maximus) for 12 weeks when tested in an experimental challenge trial [215] . However, no vaccine is currently commercially available to protect aquatic animals against Pseudomonas bacterial infections. (5) Nocardiosis caused by Nocardia sp. Nocardia bacteria are aerobic, Gram-positive, branching, filamentous and rod-shaped. Although many Nocardia species are commonly found in soil and plants [216] [217] [218] , which may be innocuous to human and animals, some Nocardia species are primary pathogen of human and animals [219] [220] [221] [222] . Recently, Nocardia sp. has been isolated from various diseased aquatic animals, including three striped tigerfish (Terapon jarbua) [123] , snakehead (Ophiocephalus argus) [124, 125] , large croaker (Pseudosciaena crocea) [126] , yellow croaker (Larimichthys crocea) [127] , striped mullet (Mugil cephalus) [128] , seabass (Lateolabrax japonicus) [129] , largemouth bass (Micropterus salmoides) [130, 131] , giant gourami (Osphronemus goramy) [132] and yellowtail (Seriola quinqueradiata) [133] . Nocardiosis is a systemic disease of fish where lesions are localized in the skin and several internal organs, with the presence of nodular lesions typical of granulomata [127] . An epizootic disease in large-mouth bass (M. salmoides) in a fresh water pond was reported to be caused by Nocardia asteroides in Taiwan in 1989, with an accumulative mortality of 30% (15 000 out of total 50 000 fish) within 1 month [131] . Nocardia sp. also caused 17.5% mortality (3500 out of 20 000 fish) within a month in pond cultured sea bass (L. japonicus) in Taiwan in 1997 [129] . In Zhejiang China, Nocardia sp. caused 35% mortality (180 000 out of 500 000) in pond-cultured snakehead (Ophiocephalus argus) in 2006 [125] . Chemotherapy for nocardiosis has been ineffective partly because the tubercles formed in diseased fish prevents access and sequestrate the organisms from the drug effect [133] . Killed vaccines have been evaluated experimentally in yellowtail and largemouth bass. Although yellowtail immunized with formalin-killed cells (FKC) of Nocardia seriolae or FKC with Freund's Incomplete Adjuvant (FKC-FIA) showed humoural responses, no protective effect was observed in immunized yellowtail [223] . Similarly, when largemouth bass (M. salmoides) were immunized with FKC of four different strains of N. seriolae, specific antibody titres were increased significantly at 4 weeks after immunization. However, immunization with different strains with or without booster immunization failed to protect largemouth bass against challenges by virulent strains of N. seriolae [224] . On the other hand, when yellowtails (S. quinqueradiata) were vaccinated with live bacteria of Nocardia soli and Nocardia fluminea cells, slight protection against an artificial challenge with N. seriolae was observed [23] . In addition, fish that survived the N. seriolae infection showed complete resistance to the N. seriolae challenge [225] , suggesting that live vaccines should be developed to protect aquatic animals against nocardiosis. (6) Staphylococcosis caused by Staphylococcus spp. Staphylococcus bacteria are important opportunistic human pathogens and leading cause of a wide variety of diseases in humans and animals [226] . For example, Staphylococcus aureus is the aetiological agent responsible for a large extent of morbidity and mortality globally, in both hospital and community settings [227, 228] . Antibiotic resistance in S. aureus is a major clinical problem, in particular in infections caused by methicillin-resistant S. aureus (MRSA) [226] . In aquatic animals, three Staphylococcus species (Staphylococcus epidermidis [142] , S. aureus [141] and Staphylococcus warneri [137] ) have been reported as disease-causing agents. S. epidermidis was reported to be the causative agent of the epizootics in cultured yellowtail (S. quinqueradiata) and red sea bream (Chrysophrys major) in Japan between 1976 and 1977 [142] . S. epidermidis was responsible for the mass mortality of tilapia between 1992 and 1996 in Taiwan [138] . S. aureus was reported to be the causative agent of an eye disease during 1982 and 1983 in India, causing mortalities in silver carp, Hypophthalmichthys molitrix [227] . S. warneri is reported to be the causative agent of a disease outbreak in a rainbow trout farm during the spring of 1997 (May-June) in Spain [137] . The typical symptoms of staphylococcosis are exophthalmia and swollen lesion on the tail [142] . Currently no vaccine against Staphylococcus spp. is commercially available or experimentally tested in aquatic animals. (7) Streptococcosis caused by Streptococcus sp. Streptococcus bacteria are important pathogens of both human and other animals. For example, S. agalactiae (group B streptococcus) is an important cause of disease in infants, pregnant women, elderly and immunesuppressed adults [229] . In addition, S. agalactiae is responsible for many cases of acute clinical mastitis in dairy animals [230, 231] . S. agalactiae also affects a variety of cultured and wild fish species in freshwater, estuarine and marine environments. These include tilapia [143, 144] , grouper [145] , mullet [146] and pomfret [147] . In August and September of 2001, S. agalactiae was responsible for a massive fish kill at the Kuwait Bay, killing over 2500 metric tonnes of wild mullet (Liza klunzingeri) [146] . In addition, S. agalactiae was reported to be the causative agent of disease outbreaks from 2007 to 2011 in Queensland, Australia in giant Queensland grouper (Epinephelus lanceolatus) [145] . No commercial vaccine against S. agalactiae is currently available in aquaculture. Experimentally, formalin-killed cells along with concentrated extracellular products (>3 kDa) of a single isolate of S. agalactiae have been reported to offer significant protection to 30 g tilapia, but not to 5 g tilapia, with a relative percent of survival (RPS) rate of 80% in vaccinated fish compared with non-vaccinated fish at 30 days post vaccination [232, 233] . However, the RPS dropped to 60, 55 and 46% at 47, 90 and 180 days post vaccination, respectively [234] . It was also reported that a formalin-killed S. agalactiae vaccine was able to increase the antibody titre in vaccinated fish compared with control fish. However, vaccination by either intraperitoneal injection or by a combination of intraperitoneal injection with oral booster vaccination (one and two doses per month) failed to protect Nile tilapia from S. agalactiae infections [235] . In addition, an experimental S. agalactiae biotype 1 (b-haemolytic) vaccine was reported to be able to offer protection against lethal challenges with both biotype 1 and biotype 2 (non-haemolytic) strains, whereas biotype II failed to offer protection against challenges with biotype 1 [236] . Recently, Merck Animal Health Inc. has obtained regulatory approval in Brazil to begin marketing AQUAVAC 1 Strep Sa, an inactivated oil-adjuvanted vaccine that provides protection against S. agalactiae infections in tilapia and other susceptible fish species. However, AQUAVAC 1 Strep Sa is only available by injection to fish weighing more than 15 g, which is rather labour-intensive. Besides S. agalactiae, S. iniae is also an important fish pathogen in aquaculture. Although bacterin vaccine is currently available in Asia to protect tilapia from S. iniae infection, it is not available for use in other parts of the world. S. iniae is responsible for a disease outbreak that killed 75% of hybrid tilapias (Tilapia niloticaÂTilapia aurea) in a Texas fish farm in USA in the early 1990s [237] . S. iniae is also the causative agent of disease outbreaks in seabream [150] , red porgy [151] , trout [151] , flounder [152] , barramundi [153] , rabbitfish [154] , yellowtail [156] and catfish [157] . The most extensively studied S. iniae vaccines are bacterins [238, 239] . These formalin-killed S. iniae have been previously successfully used as vaccines to protect rainbow trout in Israel. However, recently it has been reported that these bacterins are unable to protect fish from infection by variant isolates (serotypes) of S. iniae [240, 241] . Other vaccines consisting of both formalin killed S. iniae and concentrated extracellular products of S. iniae have been reported to partially protect Nile tilapia (Oreochromis niloticus L.) from S. iniae infection [242] [243] [244] [245] . Bacterins against S. iniae infection in tilapia are commercially available in Asia [179] . In addition to bacterins, live attenuated S. iniae strains defective in phosphoglucomutase and M-like protein have been reported to offer protection against homologous S. iniae challenge [246, 247] . However, it is not clear whether they offer protection against heterologous S. iniae. Recently, a highly efficacious attenuated S. iniae vaccine (ISNO) has been reported to protect tilapia at least 6 months against a virulent S. iniae strain [248] . In addition, ISNO is able to offer protection against heterologous virulent strains of S. iniae (F3CB, 102F1 K, 405F1 K, IF6 and ARS60) at 2-month post vaccination, with relative percent of survival of 78, 90, 100, 100 and 100%, respectively [248] . Furthermore, ISNO vaccine has a wide range of efficacious immunization dosage, with RPS values of 81, 94, 100, 100, 100 and 100 at vaccination dosage of 1Â10 2 , 1Â10 3 , 1Â10 4 , 1Â10 5 , 1Â10 6 and 1Â10 7 CFU/fish, respectively [248] . In addition to S. agalactiae and S. iniae, other Streptococcus bacteria are also emerging as important pathogens in aquaculture. For example, Streptococcus dysgalactiae is responsible for disease outbreaks in trout, sturgeon, amberjack and yellowtail [157] [158] [159] , and S. phocae is the causative agent of repeated disease outbreaks in cage-farmed Atlantic salmon in Chile since 1999, with mortality up to 25% [160] [161] [162] . Currently, no vaccine is commercially available to protect fish from infections by S. dysgalactiae or S. phocae. (8) Other emerging diseases. Besides the major diseases mentioned above, other emerging diseases can also be detrimental to the aquaculture industry, including the coldwater 'streptococcosis' caused by Vagococcus salmoninarum [163] [164] [165] , and the haemorrhagic septicaemia caused by Weissella sp. [166, 167] . Vaccines have not yet been developed to protect fish from these emerging diseases either commercially or experimentally.
Conclusion
Aquaculture is the fastest growing food-producing industry. To provide sufficient food for the ever-increasing human population, protecting the aquaculture industry from diseases is a priority. To prevent bacterial diseases, using vaccines instead of antibiotics has been proven to be effective and beneficial. Although various vaccines have been developed to protect aquatic animals against various bacterial diseases, vaccines against multiple emerging diseases are still urgently needed for the aquaculture industry. In addition, majority of the vaccines available are bacterins which can only provide partial protection against certain strains for a limited time frame. Furthermore, most vaccines have to be delivered by injection, which is labour-intensive. Therefore, user-friendly (immersion or oral delivery) efficacious vaccines that can offer broader protection for a longer duration are urgently needed for the aquaculture industry.
